Practical recommendations for systemic treatment in psoriasis according to age, pregnancy, metabolic syndrome, mental health, psoriasis subtype and treatment history (BETA-PSO: Belgian Evidence-based Treatment Advice in Psoriasis; part 1)

Lambert, J.L.W.; Segaert, S.; Ghislain, P. D.; Hillary, T.; NIKKELS, Arjen; Willaert, F.; Lambert, J.; Speeckaert, R.

doi:10.1111/jdv.16684

Article (Scientific journals)

Practical recommendations for systemic treatment in psoriasis according to age, pregnancy, metabolic syndrome, mental health, psoriasis subtype and treatment history (BETA-PSO: Belgian Evidence-based Treatment Advice in Psoriasis; part 1)

Lambert, J.L.W.; Segaert, S.; Ghislain, P. D. et al.

2020 • In Journal of the European Academy of Dermatology and Venereology, 34 (8), p. 1654-1665

Peer Reviewed verified by ORBi

Permalink
https://hdl.handle.net/2268/250522

DOI
10.1111/jdv.16684

PubMed
32735076

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

jdv.16684.pdf

Publisher postprint (405.32 kB)

Request a copy

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Keywords :

systemic treatment; psoriasis; Disorders

Abstract :

[en] Background: Impressive progress in new therapeutic options has been made for psoriasis. Treatments include topical steroids, phototherapy, conventional, synthetic disease-modifying drugs and an expanding list of biologics. Objective: The primary objective of this work was to collect evidence for the creation of practice guidelines for systemic treatment of psoriasis (BETA-PSO: Belgian Evidence-based Treatment Advice in Psoriasis). Methods: Evidence-based recommendations were formulated using a quasi-Delphi methodology after a systematic search of the literature and a consensus procedure involving 8 psoriasis experts. Results: In this part, the use of systemic treatment in different age groups, during pregnancy, in metabolic syndrome, in patients with mental health problems, in different psoriasis subtypes and in previously systemically treated patients treatment is discussed. Conclusion: Guidance on therapeutic choice in specific clinical situations in psoriasis is provided in order to facilitate the decision-making in clinical practice. © 2020 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology

Disciplines :

Dermatology

Author, co-author :

Lambert, J.L.W.; Ghent University Hospital > Department of Dermatology > Dermatology

Segaert, S.; Private practice, Tremelo, Belgium

Ghislain, P. D.; Dermatology, Cliniques Saint-Luc, Université Catholique de Louvain, Brussels, Belgium

Hillary, T.; Dermatology, University Hospital Leuven, Leuven, Belgium

NIKKELS, Arjen ; Centre Hospitalier Universitaire de Liège - CHU > Autres Services Médicaux > Service de dermatologie

Willaert, F.; Dermatology, Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium

Lambert, J.; University Hospital of Antwerp, Antwerp, Belgium

Speeckaert, R.

Language :

English

Title :

Publication date :

2020

Journal title :

Journal of the European Academy of Dermatology and Venereology

ISSN :

0926-9959

eISSN :

1468-3083

Publisher :

Blackwell Publishing Ltd

Volume :

Issue :

Pages :

1654-1665

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 02 September 2020

Statistics

Number of views

60 (6 by ULiège)

Number of downloads

2 (2 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

Bibliography

Guyatt GH, Oxman AD, Vist GE et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008; 336: 924–926.
Halkier-Sørensen L, Laurberg G Andresen J. Bone changes in children on long-term treatment with etretinate. J Am Acad Dermatol 1987; 16(5 Pt 1): 999–1006.
Sbidian E, Maza A, Montaudié H et al. Efficacy and safety of oral retinoids in different psoriasis subtypes: a systematic literature review. J Eur Acad Dermatol Venereol 2011; 25(Suppl 2): 28–33.
Diak P, Siegel J, Grenade LL, Choi L, Lemery S, McMahon A. Tumor necrosis factor α blockers and malignancy in children: Forty-eight cases reported to the food and drug administration. Arthritis Rheum 2010; 62: 2517–2524.
van Geel MJ, van de Kerkhof PCM, Oostveen AM, de Jong EMGJ, Seyger MMB. Fumaric acid esters in recalcitrant pediatric psoriasis: a prospective, daily clinical practice case series. J Dermatolog Treat 2016; 27: 214–220.
Humira 40 mg solution for injection in pre-filled syringe - Summary of Product Characteristics (SmPC) - (emc). URL https://www.medicines.org.uk/emc/product/2150/smpc (last accessed: 25 January 2020).
Enbrel 25 mg powder and solvent for solution for injection - Summary of Product Characteristics (SmPC) - (emc). URL https://www.medicines.org.uk/emc/product/3837/smpc (last accessed: 25 January 2020).
STELARA 45 mg solution for injection (vials) - Summary of Product Characteristics (SmPC) - (emc). URL https://www.medicines.org.uk/emc/product/4413/smpc (last accessed: 25 January 2020).
Ghalandari N, Dolhain RJEM, Hazes JMW et al. The pre- and post-authorisation data published by the European Medicines Agency on the use of Biologics during pregnancy and lactation. Br J Clin Pharmacol 2019; 86: 580–590.
Clowse MEB, Scheuerle AE, Chambers C et al. Pregnancy outcomes after exposure to certolizumab pegol: updated results from a pharmacovigilance safety database. Arthritis Rheumatol 2018; 70: 1399–1407.
Mariette X, Förger F, Abraham B et al. Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study. Ann Rheum Dis 2018; 77: 228–233.
Curtis JR, Mariette X, Gaujoux-Viala C et al. Long-term safety of certolizumab pegol in rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis and Crohn’s disease: a pooled analysis of 11 317 patients across clinical trials. RMD Open 2019; 5: e000942.
Plachouri K-M, Georgiou S. Special aspects of biologics treatment in psoriasis: management in pregnancy, lactation, surgery, renal impairment, hepatitis and tuberculosis. J Dermatolog Treat 2019; 30: 668–673.
Warren RB, Reich K, Langley RG et al. Secukinumab in pregnancy: outcomes in psoriasis, psoriatic arthritis and ankylosing spondylitis from the global safety database. Br J Dermatol 2018; 179: 1205–1207.
Neoral Soft Gelatin Capsules - Summary of Product Characteristics (SmPC) - (emc). URL https://www.medicines.org.uk/emc/product/1034/smpc (last accessed: 25 January 2020).
Tecfidera 120mg gastro-resistant hard capsules - Summary of Product Characteristics (SmPC) - (emc). URL https://www.medicines.org.uk/emc/product/5256/smpc#PREGNANCY (last accessed: 25 January 2020).
Methotrexate 2.5 mg Tablets - Summary of Product Characteristics (SmPC) - (emc). URL https://www.medicines.org.uk/emc/product/511/smpc (last accessed 25 January 2020).
Ilumetri 100 mg solution for injection in pre-filled syringe - Summary of Product Characteristics (SmPC) - (emc). URL https://www.medicines.org.uk/emc/product/9819/smpc (last accessed: 25 January 2020).
Otezla 30 mg Film-Coated Tablets - Summary of Product Characteristics (SmPC) - (emc). URL https://www.medicines.org.uk/emc/product/3648/smpc (last accessed 25 January 2020).
Witzel SJ. Lactation and the use of biologic immunosuppressive medications. Breastfeed Med 2014; 9: 543–546.
Gutierrez JC, Hwang K. The toxicity of methotrexate in male fertility and paternal teratogenicity. Expert Opin Drug Metab Toxicol 2017; 13: 51–58.
Mouyis M, Flint JD, Giles IP. Safety of anti-rheumatic drugs in men trying to conceive: a systematic review and analysis of published evidence. Semin Arthritis Rheum 2019; 48: 911–920.
Gordon KB, Armstrong AW, Han C et al. Anxiety and depression in patients with moderate-to-severe psoriasis and comparison of change from baseline after treatment with guselkumab vs. adalimumab: results from the Phase 3 VOYAGE 2 study. J Eur Acad Dermatol Venereol 2018; 32: 1940–1949.
Wu C-Y, Chang Y-T, Juan C-K et al. Depression and insomnia in patients with psoriasis and psoriatic arthritis taking tumor necrosis factor antagonists. Medicine (Baltimore) 2016; 95: e3816.
Strober B, Gooderham M, de Jong EMGJ et al. Depressive symptoms, depression, and the effect of biologic therapy among patients in Psoriasis Longitudinal Assessment and Registry (PSOLAR). J Am Acad Dermatol 2018; 78: 70–80.
Salame N, Ehsani-Chimeh N, Armstrong AW. Comparison of mental health outcomes among adults with psoriasis on biologic versus oral therapies: a population-based study. J Dermatolog Treat 2019; 30: 135–140.
Fleming P, Roubille C, Richer V et al. Effect of biologics on depressive symptoms in patients with psoriasis: a systematic review. J Eur Acad Dermatol Venereol 2015; 29: 1063–1070.
Griffiths CEM, Fava M, Miller AH et al. Impact of Ixekizumab treatment on depressive symptoms and systemic inflammation in patients with moderate-to-severe psoriasis: an integrated analysis of three phase 3 clinical studies. Psychother Psychosom 2017; 86: 260–267.
Mease P, Lebwohl M, Gilloteau I et al. Secukinumab treatment of psoriatic arthritis and moderate to severe psoriasis relieves anxiety/depression up to 52 weeks: an overview from secukinumab phase 3 clinical trials. Arthritis Rheumatol 2017; 69(Suppl 10): 607.
Schmieder A, Poppe M, Hametner C et al. Impact of fumaric acid esters on cardiovascular risk factors and depression in psoriasis: a prospective pilot study. Arch Dermatol Res 2015; 307: 413–424.
Lebwohl MG, Papp KA, Marangell LB et al. Psychiatric adverse events during treatment with brodalumab: analysis of psoriasis clinical trials. J Am Acad Dermatol 2018; 78: 81–89.e5.
Koo J, Ho RS Thibodeaux Q. Depression and suicidality in psoriasis and clinical studies of brodalumab: a narrative review. Cutis 2019; 104: 361–365.
Crowley J, Thaçi D, Joly P et al. Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2). J Am Acad Dermatol 2017; 77: 310–317.e1.
Thaçi D, Kimball A, Foley P et al. Apremilast, an oral phosphodiesterase 4 inhibitor, improves patient-reported outcomes in the treatment of moderate to severe psoriasis: results of two phase III randomized, controlled trials. J Eur Acad Dermatol Venereol 2017; 31: 498–506.
Schmutz J-L. Apremilast: beware of suicidal ideation and behaviour. Ann Dermatol Venereol 2017; 144: 243–244.
Gelfand JM, Shin DB, Alavi A et al. A phase IV, randomized, double-blind, placebo-controlled crossover study of the effects of ustekinumab on vascular inflammation in psoriasis (the VIP-U Trial). J Invest Dermatol 2019; 140: 85–93.e2.
Wu M-Y, Yu C-L, Yang S-J, Chi C-C. Change in body weight and body mass index in psoriasis patients receiving biologics: a systematic review and network meta-analysis. J Am Acad Dermatol 2019; 82: 101–109.
Gisondi P, Fostini AC, Fossà I, Girolomoni G, Targher G. Psoriasis and the metabolic syndrome. Clin Dermatol 2018; 36: 21–28.
Costa L, Caso F, Atteno M et al. Impact of 24-month treatment with etanercept, adalimumab, or methotrexate on metabolic syndrome components in a cohort of 210 psoriatic arthritis patients. Clin Rheumatol 2014; 33: 833–839.
Chen D-Y, Chen Y-M, Hsieh T-Y, Hsieh C-W, Lin C-C, Lan J-L. Significant effects of biologic therapy on lipid profiles and insulin resistance in patients with rheumatoid arthritis. Arthritis Res Ther 2015; 17: 52.
Al-Mutairi N Shabaan D. Effects of tumor necrosis factor α inhibitors extend beyond psoriasis: insulin sensitivity in psoriasis patients with type 2 diabetes mellitus. Cutis 2016; 97: 235–241.
Wu JJ, Rowan CG, Bebchuk JD Anthony MS. No association between TNF inhibitor and methotrexate therapy versus methotrexate in changes in hemoglobin A1C and fasting glucose among psoriasis, psoriatic arthritis, and rheumatoid arthritis patients. J Drugs Dermatol 2015; 14: 159–166.
Karadag AS, Ertugrul DT, Kalkan G et al. The effect of acitretin treatment on insulin resistance, retinol-binding protein-4, leptin, and adiponectin in psoriasis vulgaris: a noncontrolled study. Dermatology 2013; 227: 103–108.
Al-Mutairi N, Nour T. The effect of weight reduction on treatment outcomes in obese patients with psoriasis on biologic therapy: a randomized controlled prospective trial. Expert Opin Biol Ther 2014; 14: 749–756.
STELARA 45 mg solution for injection (vials) - Summary of Product Characteristics (SmPC) - (emc). URL https://www.medicines.org.uk/emc/product/4413/smpc (last accessed: 25 January 2020).
Remicade 100mg powder for concentrate for solution for infusion - Summary of Product Characteristics (SmPC) - (emc). URL https://www.medicines.org.uk/emc/product/3831/smpc#POSOLOGY (last accessed: 25 Jan 2020).
Timmermann S, Hall A. Population pharmacokinetics of brodalumab in patients with moderate to severe plaque psoriasis. Basic Clin Pharmacol Toxicol 2019; 125: 16–25.
Gordon KB, Blauvelt A, Foley P et al. Efficacy of guselkumab in subpopulations of patients with moderate-to-severe plaque psoriasis: a pooled analysis of the phase III VOYAGE 1 and VOYAGE 2 studies. Br J Dermatol 2018; 178: 132–139.
Khatri A, Eckert D, Oberoi R et al. Pharmacokinetics of risankizumab in Asian healthy subjects and patients with moderate to severe plaque psoriasis, generalized pustular psoriasis, and erythrodermic psoriasis. J Clin Pharmacol 2019; 59: 1656–1668.
Reich K, Puig L, Mallbris L, Zhang L, Osuntokun O, Leonardi C. The effect of bodyweight on the efficacy and safety of ixekizumab: results from an integrated database of three randomised, controlled Phase 3 studies of patients with moderate-to-severe plaque psoriasis. J Eur Acad Dermatol Venereol 2017; 31: 1196–1207.
Mahé E, Reguiai Z, Barthelemy H et al. Evaluation of risk factors for body weight increment in psoriatic patients on infliximab: a multicentre, cross-sectional study. J Eur Acad Dermatol Venereol 2014; 28: 151–159.
Owczarczyk-Saczonek A, Placek W Rybak-d’Obyrn J, Wygonowska E. Influence of ustekinumab on body weight of patients with psoriasis: an initial report. Postepy Dermatol Alergol 2014; 31: 29–31.
Ighani A, Georgakopoulos JR, Zhou LL, Walsh S, Shear N, Yeung J. Efficacy and safety of apremilast monotherapy for moderate to severe psoriasis: retrospective study. J Cutan Med Surg 2018; 22: 290–296.
Genre F, Armesto S, Corrales A et al. Significant sE-Selectin levels reduction after 6 months of anti-TNF-α therapy in non-diabetic patients with moderate-to-severe psoriasis. J Dermatolog Treat 2017; 28: 726–730.
Jókai H, Szakonyi J, Kontár O et al. Impact of effective tumor necrosis factor-alfa inhibitor treatment on arterial intima-media thickness in psoriasis: results of a pilot study. J Am Acad Dermatol 2013; 69: 523–529.
Wu JJ, Guérin A, Sundaram M, Dea K, Cloutier M, Mulani P. Cardiovascular event risk assessment in psoriasis patients treated with tumor necrosis factor-α inhibitors versus methotrexate. J Am Acad Dermatol 2017; 76: 81–90.
Lee MP, Desai RJ, Jin Y, Brill G, Ogdie A Kim SC. Association of ustekinumab vs TNF inhibitor therapy with risk of atrial fibrillation and cardiovascular events in patients with psoriasis or psoriatic arthritis. JAMA Dermatol 2019; 155: 700–707.
von Stebut E, Reich K, Thaçi D et al. Impact of secukinumab on endothelial dysfunction and other cardiovascular disease parameters in psoriasis patients over 52 weeks. J Invest Dermatol 2019; 139: 1054–1062.
Elnabawi YA, Dey AK, Goyal A et al. Coronary artery plaque characteristics and treatment with biologic therapy in severe psoriasis: results from a prospective observational study. Cardiovasc Res 2019; 115: 721–728.
Conway R, Low C, Coughlan RJ, O’Donnell MJ, Carey JJ. Risk of liver injury among methotrexate users: a meta-analysis of randomised controlled trials. Semin Arthritis Rheum 2015; 45: 156–162.
Jüngst C, Kim Y-J, Lammert F. Severe drug-induced liver injury related to therapy with dimethyl fumarate. Hepatology 2016; 64: 1367–1369.
Muñoz MA, Kulick CG, Kortepeter CM, Levin RL, Avigan MI. Liver injury associated with dimethyl fumarate in multiple sclerosis patients. Mult Scler 2017; 23: 1947–1949.
Chularojanamontri L, Silpa-Archa N, Wongpraparut C Limphoka P. Long-term safety and drug survival of acitretin in psoriasis: a retrospective observational study. Int J Dermatol 2019; 58: 593–599.
Crowley JJ, Weinberg JM, Wu JJ, Robertson AD Van Voorhees AS. Treatment of nail psoriasis: best practice recommendations from the Medical Board of the National Psoriasis Foundation. JAMA Dermatol 2015; 151: 87–94.
Foley P, Gordon K, Griffiths CEM et al. Efficacy of guselkumab compared with adalimumab and placebo for psoriasis in specific body regions: a secondary analysis of 2 randomized clinical trials. JAMA Dermatol 2018; 154: 676–683.
Elewski BE, Okun MM, Papp K et al. Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial. J Am Acad Dermatol 2018; 78: 90–99.e1.
Papp KA, Blauvelt A, Bukhalo M et al. Risankizumab versus ustekinumab for moderate-to-severe plaque psoriasis. N Engl J Med 2017; 376: 1551–1560.
Rigopoulos D, Baran R, Chiheb S et al. Recommendations for the definition, evaluation, and treatment of nail psoriasis in adult patients with no or mild skin psoriasis: A dermatologist and nail expert group consensus. J Am Acad Dermatol 2019; 81: 228–240.
Frambach Y, Galli E, Mohr M, Zillikens D, Ludwig R.Fun or no fun? Efficacy of fumaric acid esters in nail psoriasis: results of the FUN study. Poster presented at 23th World Congress of Dermatology (Vancouver); 2015.
Morita A, Yamazaki F, Matsuyama T et al. Adalimumab treatment in Japanese patients with generalized pustular psoriasis: results of an open-label phase 3 study. J Dermatol 2018; 45: 1371–1380.
Imafuku S, Honma M, Okubo Y et al. Efficacy and safety of secukinumab in patients with generalized pustular psoriasis: A 52-week analysis from phase III open-label multicenter Japanese study. J Dermatol 2016; 43: 1011–1017.
Saeki H, Nakagawa H, Nakajo K et al. Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: results from a 52-week, open-label, phase 3 study (UNCOVER-J). J Dermatol 2017; 44: 355–362.
Yamasaki K, Nakagawa H, Kubo Y Ootaki K. Efficacy and safety of brodalumab in patients with generalized pustular psoriasis and psoriatic erythroderma: results from a 52-week, open-label study. Br J Dermatol 2017; 176: 741–751.
Sano S, Kubo H, Morishima H, Goto R, Zheng R, Nakagawa H. Guselkumab, a human interleukin-23 monoclonal antibody in Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis: efficacy and safety analyses of a 52-week, phase 3, multicenter, open-label study. J Dermatol 2018; 45: 529–539.
Kearns DG, Chat VS, Zang PD, Han G, Wu JJ. Review of treatments for generalized pustular psoriasis manuscript. J Dermatolog Treat 2019: 1–13.
Choon SE, Lai NM, Mohammad NA, Nanu NM, Tey KE, Chew SF. Clinical profile, morbidity, and outcome of adult-onset generalized pustular psoriasis: analysis of 102 cases seen in a tertiary hospital in Johor, Malaysia. Int J Dermatol 2014; 53: 676–684.
Rosenbach M, Hsu S, Korman NJ et al. Treatment of erythrodermic psoriasis: from the medical board of the National Psoriasis Foundation. J Am Acad Dermatol 2010; 62: 655–662.
Singh RK, Lee KM, Ucmak D et al. Erythrodermic psoriasis: pathophysiology and current treatment perspectives. Psoriasis (Auckl) 2016; 6: 93–104.
Pescitelli L, Dini V, Gisondi P et al. Erythrodermic psoriasis treated with ustekinumab: an Italian multicenter retrospective analysis. J Dermatol Sci 2015; 78: 149–151.
Mateu-Puchades A, Santos-Alarcón S, Martorell-Calatayud A, Pujol-Marco C, Sánchez-Carazo J-L. Erythrodermic psoriasis and secukinumab: our clinical experience. Dermatol Ther 2018; 31: e12607.
Cozzani E, Wei Y, Burlando M, Signori A, Parodi A. Serial biologic therapies in psoriasis patients: A 12-year, single-center, retrospective observational study. J Am Acad Dermatol 2019; 82: 37–44.
Kimmel G, Chima M, Kim HJ et al. Brodalumab in the treatment of moderate to severe psoriasis in patients when previous anti-interleukin 17A therapies have failed. J Am Acad Dermatol 2019; 81: 857–859.
Wang T-S Tsai T-F. Biologics switch in psoriasis. Immunotherapy 2019; 11: 531–541.
Segaert S, Ghislain P-D, Boone C. An observational study of the real-life management of psoriasis patients treated with etanercept according to the new reimbursement criteria (in Belgium). J Dermatolog Treat 2016; 27: 103–109.
Choi CW, Choi JY, Kim BR, Youn SW. Economic burden can be the major determining factor resulting in short-term intermittent and repetitive ustekinumab treatment for moderate-to-severe psoriasis. Ann Dermatol 2018; 30: 179–185.
Tzaneva S, Geroldinger A, Trattner H, Tanew A. Fumaric acid esters in combination with a 6-week course of narrowband ultraviolet B provides an accelerated response compared with fumaric acid esters monotherapy in patients with moderate-to-severe plaque psoriasis: a randomized prospective clinical study. Br J Dermatol 2018; 178: 682–688.
Langley R, Blauvelt A, Gooderham M et al. Efficacy and safety of continuous Q12W risankizumab versus treatment withdrawal: results from the phase 3 IMMhance Trial. J Am Acad Dermatol 2019; 81: AB52.
Reich K, Armstrong AW, Foley P et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol 2017; 76: 418–431.
Reich K, Wozel G, Zheng H, van Hoogstraten HJF, Flint L, Barker J. Efficacy and safety of infliximab as continuous or intermittent therapy in patients with moderate-to-severe plaque psoriasis: results of a randomized, long-term extension trial (RESTORE2). Br J Dermatol 2013; 168: 1325–1334.
Jørgensen KK, Olsen IC, Goll GL et al. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. Lancet 2017; 389: 2304–2316.
Bennett WM. Drug-related renal dysfunction in the elderly. In Oreopoulos DG, Hazzard WR, Luke R, eds. Nephrology and Geriatrics Integrated: Proceedings of the Conference on Integrating Geriatrics into Nephrology held in Jasper, Alberta, Canada, July 31-August 5, 1998. Springer Netherlands, Dordrecht, 2000: 45–50. https://doi.org/10.1007/978-94-011-4088-1_5
Saurat J-H, Guérin A, Yu AP et al. High prevalence of potential drug-drug interactions for psoriasis patients prescribed methotrexate or cyclosporine for psoriasis: associated clinical and economic outcomes in real-world practice. Dermatology 2010; 220: 128–137.